<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04052347</url>
  </required_header>
  <id_info>
    <org_study_id>HSC-MS-19-0490</org_study_id>
    <nct_id>NCT04052347</nct_id>
  </id_info>
  <brief_title>Decision Aid to Assist Low-Risk Nulliparous Women Considering Induction of Labor At 39 Weeks</brief_title>
  <acronym>DAWN</acronym>
  <official_title>Decision Aid to Assist Low-Risk Nulliparous Women Considering Induction of Labor At 39 Weeks: A Randomized Trial (DAWN Trial)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Texas Health Science Center, Houston</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The University of Texas Health Science Center, Houston</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective is to assess if the utilization of a decision-aid increases the
      likelihood of low-risk nulliparous women undergoing elective induction of labor at 39.0-39.6
      weeks
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 1, 2019</start_date>
  <completion_date type="Anticipated">September 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assess if the utilization of a decision-aid</measure>
    <time_frame>4 weeks</time_frame>
    <description>Number of subjects who decided to undergo elective induction of labor at 39.0-39.6 weeks after utilization of a decision-aid</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Composite neonatal morbidity</measure>
    <time_frame>at delivery</time_frame>
    <description>Composite neonatal morbidity among (CNM) is any of the following: 1) Apgar score &lt; 7 at 5 min, 2) umbilical arterial pH &lt; 7.00, 3) intraventricular hemorrhage grade III or IV, 4) periventricular leukomalacia, 5) intubation for over 24 hrs, 6) necrotizing enterocolitis grade 2 or 3, 7) stillbirth or 8) death within 28 days of birth.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maternal morbidities</measure>
    <time_frame>1 week</time_frame>
    <description>Number of subjects with morbidities as described by American College of Obstetrics and Gynecology (ACOG)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">314</enrollment>
  <condition>Pregnancy Related</condition>
  <condition>Elective Induction</condition>
  <arm_group>
    <arm_group_label>Shared decision-making with a patient decision-aid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>routine shared decision-making</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>control group</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Shared decision-making with a Decision-aid</intervention_name>
    <description>A tablet computer-based decision-aid was developed by the study investigators based on the standards of the International Patient Decision Aid Standards Collaboration9</description>
    <arm_group_label>Shared decision-making with a patient decision-aid</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>routine shared decision-making</intervention_name>
    <description>control group</description>
    <arm_group_label>routine shared decision-making</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Low-risk nulliparous women- no previous pregnancy &gt; 23 weeks

          -  18-50 years of age

          -  Singleton gestation

          -  Between 34.0 and 36.6 weeks at the time of screening. Randomization must occur between
             37.0-37.6 weeks inclusive.

        Exclusion Criteria:

          -  1. First sonographic examination after 20 weeks 2. Women with any of the following
             comorbidities (at the time of randomization):

               1. Autoimmune disorders (antiphospholipid antibody, lupus, rheumatoid arthritis,
                  scleroderma)

               2. Cerclage in the index pregnancy

               3. Diabetes mellitusâ€”gestational or pre-gestational

               4. Hematologic disorders (coagulation defects, sickle cell disease,
                  thrombocytopenia, thrombophilia)

               5. Hypertension (chronic or pregnancy induced) before enrollment

               6. HIV (human immunodeficiency virus)

               7. Institutionalized individuals (prisoners)

               8. Prior obstetric history of: 1) intrauterine growth restriction, 2) preterm birth
                  before 34 weeks, 3) severe preeclampsia, eclampsia, HELLP syndrome, and 4)
                  stillbirth after 24 weeks or neonatal death

               9. Preterm labor or ruptured membranes before enrollment

              10. Psychiatric disorder (bipolar, depression) on medication

              11. Placenta previa / 3rd trimester bleeding

              12. Renal insufficiency (serum creatinine &gt; 1.5 mg/dL)

              13. Restrictive lung disease

              14. Fetal red blood cell isoimmunization

              15. Seizure disorder on medication

              16. Thyroid disease on medication

              17. Body Mass Index (BMI) above 40 kg/m 3. Major fetal Anomaly including:
                  anencephaly, spina bifida, bilateral renal agenesis, cystic hygroma with hydrops,
                  diaphragmatic hernia, or congenital heart defects 4. Unable to understand consent
                  in English or Spanish
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Megha Gupta, MD</last_name>
    <phone>713-500-6412</phone>
    <email>megha.gupta@uth.tmc.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sunbola Ashimi, PhD</last_name>
    <phone>713-500-6410</phone>
    <email>sunbola.s.ashimi@uth.tmc.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The University of Texas Health Science Center at Houston</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>July 15, 2019</study_first_submitted>
  <study_first_submitted_qc>August 6, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 9, 2019</study_first_posted>
  <last_update_submitted>August 6, 2019</last_update_submitted>
  <last_update_submitted_qc>August 6, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 9, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The University of Texas Health Science Center, Houston</investigator_affiliation>
    <investigator_full_name>Megha Gupta</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

